4//SEC Filing
Fairmount Healthcare Fund II L.P. 4
Accession 0001636282-25-000069
CIK 0001636282other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:39 PM ET
Size
14.4 KB
Accession
0001636282-25-000069
Insider Transaction Report
Form 4
Fairmount Funds Management LLC
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Peter Harwin)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying) - Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Tomas Kiselak)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying)
Harwin Peter Evan
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Tomas Kiselak)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying) - Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Peter Harwin)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying)
Kiselak Tomas
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Peter Harwin)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying) - Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Tomas Kiselak)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying)
Transactions
- Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Tomas Kiselak)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying) - Award
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total(indirect: By Peter Harwin)Exercise: $15.55Exp: 2035-05-29→ Common Stock (25,000 underlying)
Footnotes (4)
- [F1]This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date.
- [F2]Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.
- [F3]This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date.
- [F4]Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.
Documents
Issuer
Spyre Therapeutics, Inc.
CIK 0001636282
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001769651
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 4:39 PM ET
- Size
- 14.4 KB